Join to View Full Profile
55 Fruit StreetBoston, MA 02114
Phone+1 617-726-2000
Dr. Branagan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2010 - 2012
University of Illinois College of Medicine at ChicagoInternship, Internal Medicine, 2009 - 2010
Ben Gurion University of the NegevClass of 2009
Certifications & Licensure
CA State Medical License 2024 - 2026
MA State Medical License 2017 - 2026
PA State Medical License 2021 - 2026
MD State Medical License 2021 - 2024
NH State Medical License 2024 - 2024
NC State Medical License 2021 - 2023
ME State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Start of enrollment: 2015 Sep 01
- A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2021 May 13
- ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy Start of enrollment: 2021 Nov 16
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment.Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury
Blood. 2025-03-31 - Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury.E Bridget Kim, Jack E Malespini, Matthew Lei, Samuel S Han, Cole W Minsky
Blood Advances. 2025-03-14 - 2 citationsElotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2025-03-11
Press Mentions
Patients with Multiple Myeloma and Waldenström Macroglobulinemia Have Impaired COVID-19 Vaccine ResponsivenessDecember 11th, 2021
Dr. Branagan on Tandem Transplants in Multiple MyelomaMarch 2nd, 2020
More Work Needed to Determine Best Treatment for High-Risk MyelomaFebruary 29th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
